UroStream

From April 11 to 13, 2025, the 5th Chinese Urological Doctor Association Yanqi Lake Meeting—jointly organized by the Chinese Medical Doctor Association and Chinese Urological Doctor Association—was successfully held in Beijing. The event brought together prominent experts from across the country to explore the future of urology in China. UroStream invited Professor Nianzeng Xing, President of the Chinese Urological Doctor Association and expert from the Cancer Hospital, Chinese Academy of Medical Sciences, to discuss the meeting highlights, the importance of multidisciplinary collaboration, and efforts to improve care in grassroots hospitals.

Currently, ADT remains the cornerstone treatment regimen for mHSPC. However, long-term use of ADT may increase the risk of cardiovascular events. Recently, the data from the STAMPEDE study presented at the European Association of Urology (EAU) Congress showed that the combination of metformin and ADT can extend the overall survival of patients with high tumor burden mHSPC by 10 months (hazard ratio [HR] = 0.79). At the same time, it can also improve metabolic indicators: there is less weight gain (2.5 kg vs 4 kg) and a lower incidence of metabolic syndrome (4.9% vs 9.4%). UroStream specially invited the study presenter, Dr. Ashwin Sachdeva, a senior clinical lecturer in University of Manchester, Division of Cancer Sciences, to share the wonderful content on-site.

Bladder cancer is a biologically heterogeneous disease, and its classification plays a critical role in guiding treatment. However, current bladder cancer classification remains based primarily on clinical-pathological features or staging, with molecular subtyping yet to be standardized. At the 2025 European Association of Urology (EAU) Congress, Dr. Jeffrey S. Damrauer from the UNC Lineberger Comprehensive Cancer Center shared key insights on the response of different bladder cancer types to treatment, the role of neoadjuvant therapy, and the growing possibilities of bladder-sparing strategies.

For patients with non-muscle-invasive bladder cancer (NMIBC) who do not respond to Bacillus Calmette-Guérin (BCG) therapy, clinicians and researchers are actively exploring novel treatment strategies. Among these, oncolytic virus therapy has emerged as a promising approach. At the 40th Annual EAU Congress, Dr. Siamak Daneshmand from the University of Southern California (USC) presented two key studies on oncolytic viruses—the BOND-003 P cohort and the PIVOT-006 trial. UroStream invited Professor Daneshmand to discuss the mechanism of action, safety, efficacy, and future directions of this innovative therapy.

In recent years, prostate-specific membrane antigen (PSMA) molecular imaging technology has demonstrated significant value in the diagnosis and treatment of prostate cancer. It has improved the accuracy of clinical staging, supported multimodal treatment decision-making, and facilitated the development of precision medicine through novel radioligand therapies. At the recent EAU Congress, UroStream invited Professor Xuefeng Qiu from Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School,Nanjing University, to share insights into his team’s research on PSMA PET/CT for predicting biochemical recurrence (BCR), the impact of tumor heterogeneity, and the clinical experience at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School，Nanjing University.

At the highly anticipated Game Changer Session at EAU25, Professor Declan Murphy (Peter MacCallum Cancer Centre, Melbourne) delivered an impactful presentation on the results of the TRANSLATE trial, a multicentre,…

In a Game Changer Session at EAU25, Prof. Kellokumpu-Lehtinen Pirkko-Liisa presented the 10-year follow-up from the Scandinavian Prostate Cancer Study Group-13 trial (SPCG-13), exploring adjuvant docetaxel versus surveillance following curative…

At EAU25, Dr. Mehmet Cetin from Marmara University School of Medicine (Istanbul) presented a prospective randomized controlled study evaluating the impact of video-based informed consent on the anxiety levels of…

At #EAU25, Professor Xiongjun Ye (叶雄俊) from Peking Union Medical College Hospital shared his team’s latest findings on MRI accuracy in renal tumor diagnosis, tumor heterogeneity in RCC, and strategies for managing postoperative recurrence. His group’s EAU-selected research explores how imaging limitations and intratumoral heterogeneity affect treatment outcomes—offering new perspectives for optimizing RCC care.

At #EAU25, we spoke with Prof. Haibin Chen and Prof. Ruiyi Zhang from Renji Hospital, Shanghai Jiao Tong University, who shared updates on their team's research in muscle-invasive bladder cancer (MIBC). They discussed a new study exploring ADC therapy for HER2+ MIBC, as well as progress in bladder-sparing treatment, ctDNA-based monitoring, and AI-driven molecular profiling for personalized treatment decisions.